United States Biotechnology & Medical Research

Avalo Therapeutics Inc (AVTX)

Track

Avalo Therapeutics Inc. experienced significant selling activity recently, with insiders offloading shares totaling over 830,000 USD. These transactions occurred following the company's latest earnings report, which showed a negative surprise. Executives, including the Chief Medical Officer and Financial Officer, executed multiple planned divestments amidst stable stock performance over the past quarter.
Ticker: AVTX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Avalo Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Riley Jennifer Chief Strategy Officer Officer
Transaction date
Sale
Price
65.10
Quantity 76,530 +15.5%
Value US$1,943,511
JENNIFER RILEY Officer Officer
Transaction date
Proposed sale
Price
23.22
Quantity 3,471
Value US$1,285,884
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
497.79
Quantity 51,114 +14.8%
Value US$863,267
2.3
MITTIE DOYLE Officer Officer
Transaction date
Proposed sale
Price
18.32
Quantity 1,000
Value US$100,000
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
20.00
Quantity 1,000 -1.9%
Value US$100,000
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
20.00
Quantity 4,654 -8.2%
Value US$93,080
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.00
Quantity 1,450 -2.7%
Value US$26,100
0.8
JONATHAN GOLDMAN Director Non-Executive Director
Transaction date
Proposed sale
Price
14.39
Quantity 42,833
Value US$616,226
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
16.00
Quantity 679 -1.4%
Value US$10,864
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.76
Quantity 3,000 -45.3%
Value US$56,280
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
24.12
Quantity 18,606 -97.8%
Value US$448,818
CHRISTOPHER SULLIVAN Officer Officer
Transaction date
Proposed sale
Price
21.81
Quantity 18,606
Value US$405,797
VARKI PAUL Chief Legal Officer Officer
Transaction date
Planned sale
Price
23.71
Quantity 400 -9.9%
Value US$9,484
VARKI PAUL Chief Legal Officer Officer
Transaction date
Planned sale
Price
22.70
Quantity 9,253 -69.6%
Value US$210,029
VARKI PAUL Chief Legal Officer Officer
Transaction date
Planned sale
Price
21.22
Quantity 22,839 -63.2%
Value US$484,541
VARKI PAUL Chief Legal Officer Officer
Transaction date
Planned sale
Price
19.78
Quantity 5,196 -12.6%
Value US$102,783
VARKI PAUL Chief Legal Officer Officer
Transaction date
Planned sale
Price
18.91
Quantity 37,375 -47.5%
Value US$706,836
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
22.57
Quantity 8,900 -95.5%
Value US$200,913
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
21.37
Quantity 9,219 -49.7%
Value US$197,008
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
20.76
Quantity 2,700 -12.7%
Value US$56,052
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
19.28
Quantity 12,347 -36.8%
Value US$238,093
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
18.55
Quantity 13,834 -29.2%
Value US$256,655
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
22.88
Quantity 10,058 -73.5%
Value US$230,127
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
22.41
Quantity 19,015 -58.2%
Value US$426,050
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
21.20
Quantity 44,944 -57.9%
Value US$952,669
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
19.65
Quantity 5,000 -6.1%
Value US$98,251
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.03
Quantity 27,538 -25.0%
Value US$496,405
Chan Mitchell Non-Executive Director
Transaction date
Planned sale
Price
22.88
Quantity 3,167 -50.0%
Value US$72,461
2.3
MITTIE DOYLE Officer Officer
Transaction date
Proposed sale
Price
16.26
Quantity 54,508
Value US$886,300
CHRISTOPHER SULLIVAN Officer Officer
Transaction date
Proposed sale
Price
16.26
Quantity 47,000
Value US$764,220
PAUL VARKI Officer Officer
Transaction date
Proposed sale
Price
16.26
Quantity 92,771
Value US$1,508,456
MITCHELL CHAN Director Non-Executive Director
Transaction date
Proposed sale
Price
16.26
Quantity 3,167
Value US$51,495
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
16.00
Quantity 1,679 -31.7%
Value US$26,864
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
13.23
Quantity 8,457 -95.2%
Value US$111,853
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
13.09
Quantity 8,458 -48.8%
Value US$110,736
CHRISTOPHER SULLIVAN Officer Officer
Transaction date
Proposed sale
Price
12.86
Quantity 16,915
Value US$217,527
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.01
Quantity 3,970 -52.3%
Value US$71,508
2.3
MITTIE DOYLE Officer Officer
Transaction date
Proposed sale
Price
17.76
Quantity 65,800
Value US$1,168,608
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
17.57
Quantity 1,780 -9.3%
Value US$31,270
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
17.02
Quantity 6,200 -24.5%
Value US$105,553
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
16.83
Quantity 7,479 -22.8%
Value US$125,841
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
15.86
Quantity 500 -1.5%
Value US$7,929
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
16.00
Quantity 679 -15.8%
Value US$10,864
CHRISTOPHER SULLIVAN Officer Officer
Transaction date
Proposed sale
Price
14.93
Quantity 15,959
Value US$238,268
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Sale
Price
16.15
Quantity 25,492 -87.6%
Value US$411,607
2.3
MITTIE DOYLE Officer Officer
Transaction date
Proposed sale
Price
15.80
Quantity 29,529
Value US$466,558
0.8
Goldman Jonathan Non-Executive Director
Transaction date
Sale
Price
14.35
Quantity 8,200 -100.0%
Value US$117,649
0.8
Goldman Jonathan Non-Executive Director
Transaction date
Sale
Price
14.30
Quantity 3,167 -100.0%
Value US$45,288
3.6
Almenoff June Sherie Non-Executive Director
Transaction date
Purchase
Price
13.00
Quantity 500 +100.0%
Value US$6,500
3.6
Almenoff June Sherie Non-Executive Director
Transaction date
Purchase
Price
12.50
Quantity 500 +inf%
Value US$6,250
2.5
ARMISTICE CAPITAL, LLC Large shareholder
Transaction date
Sale
Price
0.52
Quantity 937,404 -56.2%
Value US$486,888
2.5
ARMISTICE CAPITAL, LLC Large shareholder
Transaction date
Sale
Price
0.61
Quantity 2,746,138 -62.2%
Value US$1,682,010
NEIL GARRY ARTHUR CEO and Chairman of the Board Executive Director
Transaction date
Planned purchase
Price
3.42
Quantity 4,000 +43.4%
Value US$13,680
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned purchase
Price
3.42
Quantity 511 +68.0%
Value US$1,748
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-12 2026-08-11 S Sale
Riley Jennifer

Chief Strategy Officer

Officer
76,530 +15.5%
65.10
US$1,943,511 		76,530 +15.5% 65.10 US$1,943,511
2026-08-11 2026-08-11 PrS Proposed sale
JENNIFER RILEY

Officer

Officer
3,471
23.22
US$1,285,884 		3,471 23.22 US$1,285,884
2026-08-12 2026-08-10 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
51,114 +14.8%
497.79
US$863,267 		51,114 +14.8% 497.79 US$863,267
2026-08-10 2026-08-10 PrS Proposed sale
2.3
MITTIE DOYLE

Officer

Officer
1,000
18.32
US$100,000 		1,000 18.32 US$100,000
2026-07-29 2026-07-27 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
1,000 -1.9%
20.00
US$100,000 		1,000 -1.9% 20.00 US$100,000
2026-07-02 2026-06-30 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
4,654 -8.2%
20.00
US$93,080 		4,654 -8.2% 20.00 US$93,080
2026-06-25 2026-06-23 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
1,450 -2.7%
18.00
US$26,100 		1,450 -2.7% 18.00 US$26,100
2026-06-02 2026-06-02 PrS Proposed sale
0.8
JONATHAN GOLDMAN

Director

Non-Executive Director
42,833
14.39
US$616,226 		42,833 14.39 US$616,226
2026-06-01 2026-05-28 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
679 -1.4%
16.00
US$10,864 		679 -1.4% 16.00 US$10,864
2026-05-19 2026-05-15 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
3,000 -45.3%
18.76
US$56,280 		3,000 -45.3% 18.76 US$56,280
2026-05-11 2026-05-07 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
18,606 -97.8%
24.12
US$448,818 		18,606 -97.8% 24.12 US$448,818
2026-05-07 2026-05-07 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
18,606
21.81
US$405,797 		18,606 21.81 US$405,797
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
400 -9.9%
23.71
US$9,484 		400 -9.9% 23.71 US$9,484
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
9,253 -69.6%
22.70
US$210,029 		9,253 -69.6% 22.70 US$210,029
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
22,839 -63.2%
21.22
US$484,541 		22,839 -63.2% 21.22 US$484,541
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
5,196 -12.6%
19.78
US$102,783 		5,196 -12.6% 19.78 US$102,783
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
37,375 -47.5%
18.91
US$706,836 		37,375 -47.5% 18.91 US$706,836
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
8,900 -95.5%
22.57
US$200,913 		8,900 -95.5% 22.57 US$200,913
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
9,219 -49.7%
21.37
US$197,008 		9,219 -49.7% 21.37 US$197,008
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
2,700 -12.7%
20.76
US$56,052 		2,700 -12.7% 20.76 US$56,052
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
12,347 -36.8%
19.28
US$238,093 		12,347 -36.8% 19.28 US$238,093
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
13,834 -29.2%
18.55
US$256,655 		13,834 -29.2% 18.55 US$256,655
2026-05-07 2026-05-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
10,058 -73.5%
22.88
US$230,127 		10,058 -73.5% 22.88 US$230,127
2026-05-07 2026-05-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
19,015 -58.2%
22.41
US$426,050 		19,015 -58.2% 22.41 US$426,050
2026-05-07 2026-05-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
44,944 -57.9%
21.20
US$952,669 		44,944 -57.9% 21.20 US$952,669
2026-05-07 2026-05-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
5,000 -6.1%
19.65
US$98,251 		5,000 -6.1% 19.65 US$98,251
2026-05-07 2026-05-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
27,538 -25.0%
18.03
US$496,405 		27,538 -25.0% 18.03 US$496,405
2026-05-07 2026-05-06 PlS Planned sale
Chan Mitchell
Non-Executive Director
3,167 -50.0%
22.88
US$72,461 		3,167 -50.0% 22.88 US$72,461
2026-05-06 2026-05-06 PrS Proposed sale
2.3
MITTIE DOYLE

Officer

Officer
54,508
16.26
US$886,300 		54,508 16.26 US$886,300
2026-05-06 2026-05-06 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
47,000
16.26
US$764,220 		47,000 16.26 US$764,220
2026-05-06 2026-05-06 PrS Proposed sale
PAUL VARKI

Officer

Officer
92,771
16.26
US$1,508,456 		92,771 16.26 US$1,508,456
2026-05-06 2026-05-06 PrS Proposed sale
MITCHELL CHAN

Director

Non-Executive Director
3,167
16.26
US$51,495 		3,167 16.26 US$51,495
2026-05-07 2026-05-05 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
1,679 -31.7%
16.00
US$26,864 		1,679 -31.7% 16.00 US$26,864
2026-05-01 2026-04-30 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
8,457 -95.2%
13.23
US$111,853 		8,457 -95.2% 13.23 US$111,853
2026-05-01 2026-04-29 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
8,458 -48.8%
13.09
US$110,736 		8,458 -48.8% 13.09 US$110,736
2026-04-29 2026-04-29 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
16,915
12.86
US$217,527 		16,915 12.86 US$217,527
2026-04-08 2026-04-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
3,970 -52.3%
18.01
US$71,508 		3,970 -52.3% 18.01 US$71,508
2026-04-06 2026-04-06 PrS Proposed sale
2.3
MITTIE DOYLE

Officer

Officer
65,800
17.76
US$1,168,608 		65,800 17.76 US$1,168,608
2026-04-03 2026-04-02 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
1,780 -9.3%
17.57
US$31,270 		1,780 -9.3% 17.57 US$31,270
2026-04-03 2026-04-02 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
6,200 -24.5%
17.02
US$105,553 		6,200 -24.5% 17.02 US$105,553
2026-04-03 2026-04-01 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
7,479 -22.8%
16.83
US$125,841 		7,479 -22.8% 16.83 US$125,841
2026-04-03 2026-04-01 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
500 -1.5%
15.86
US$7,929 		500 -1.5% 15.86 US$7,929
2026-04-03 2026-04-01 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
679 -15.8%
16.00
US$10,864 		679 -15.8% 16.00 US$10,864
2026-04-01 2026-04-01 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
15,959
14.93
US$238,268 		15,959 14.93 US$238,268
2026-03-18 2026-03-16 S Sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
25,492 -87.6%
16.15
US$411,607 		25,492 -87.6% 16.15 US$411,607
2026-03-16 2026-03-16 PrS Proposed sale
2.3
MITTIE DOYLE

Officer

Officer
29,529
15.80
US$466,558 		29,529 15.80 US$466,558
2025-11-17 2025-11-14 S Sale
0.8
Goldman Jonathan
Non-Executive Director
8,200 -100.0%
14.35
US$117,649 		8,200 -100.0% 14.35 US$117,649
2025-11-17 2025-11-14 S Sale
0.8
Goldman Jonathan
Non-Executive Director
3,167 -100.0%
14.30
US$45,288 		3,167 -100.0% 14.30 US$45,288
2024-11-14 2024-11-13 B Purchase
3.6
Almenoff June Sherie
Non-Executive Director
500 +100.0%
13.00
US$6,500 		500 +100.0% 13.00 US$6,500
2024-11-14 2024-11-12 B Purchase
3.6
Almenoff June Sherie
Non-Executive Director
500 +inf%
12.50
US$6,250 		500 +inf% 12.50 US$6,250
2023-06-28 2023-06-27 S Sale
2.5
ARMISTICE CAPITAL, LLC
Large shareholder
937,404 -56.2%
0.52
US$486,888 		937,404 -56.2% 0.52 US$486,888
2023-06-28 2023-06-26 S Sale
2.5
ARMISTICE CAPITAL, LLC
Large shareholder
2,746,138 -62.2%
0.61
US$1,682,010 		2,746,138 -62.2% 0.61 US$1,682,010
2023-06-20 2023-06-20 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,000 +0.1%
4.14
US$8,289 		2,000 +0.1% 4.14 US$8,289
2023-06-20 2023-06-16 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
3,000 +0.2%
3.90
US$11,714 		3,000 +0.2% 3.90 US$11,714
2023-06-20 2023-06-15 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
3,160 +0.2%
3.68
US$11,640 		3,160 +0.2% 3.68 US$11,640
2023-06-14 2023-06-14 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
6,000 +0.4%
3.48
US$20,874 		6,000 +0.4% 3.48 US$20,874
2023-06-14 2023-06-13 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
8,750 +0.6%
3.82
US$33,439 		8,750 +0.6% 3.82 US$33,439
2023-06-14 2023-06-12 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,149 +0.2%
4.34
US$9,316 		2,149 +0.2% 4.34 US$9,316
2023-06-13 2023-06-09 PP Planned purchase
NEIL GARRY ARTHUR

CEO and Chairman of the Board

Executive Director
4,000 +43.4%
3.42
US$13,680 		4,000 +43.4% 3.42 US$13,680
2023-06-13 2023-06-09 PP Planned purchase
Sullivan Christopher Ryan

Chief Financial Officer

Officer
511 +68.0%
3.42
US$1,748 		511 +68.0% 3.42 US$1,748
2023-06-09 2023-06-09 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
5,044 +0.4%
4.14
US$20,896 		5,044 +0.4% 4.14 US$20,896
2023-06-09 2023-06-08 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
6,398 +0.5%
3.93
US$25,126 		6,398 +0.5% 3.93 US$25,126
2023-06-09 2023-06-07 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,984 +0.2%
3.49
US$10,418 		2,984 +0.2% 3.49 US$10,418
2023-06-02 2023-05-31 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
844 +0.1%
2.87
US$2,422 		844 +0.1% 2.87 US$2,422
2023-05-30 2023-05-30 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
671 +0.0%
2.87
US$1,924 		671 +0.0% 2.87 US$1,924
2023-05-30 2023-05-25 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,000 +0.1%
2.77
US$5,540 		2,000 +0.1% 2.77 US$5,540
2023-05-24 2023-05-24 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
5,519 +0.4%
2.96
US$16,348 		5,519 +0.4% 2.96 US$16,348
2023-05-24 2023-05-24 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
3,481 +0.3%
3.01
US$10,468 		3,481 +0.3% 3.01 US$10,468
2023-05-22 2023-05-22 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
7,000 +0.5%
3.34
US$23,358 		7,000 +0.5% 3.34 US$23,358
2023-05-22 2023-05-19 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
6,500 +0.5%
3.52
US$22,852 		6,500 +0.5% 3.52 US$22,852
2023-05-22 2023-05-18 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
13,121 +1.0%
3.29
US$43,163 		13,121 +1.0% 3.29 US$43,163
2023-05-16 2023-05-16 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
379 +0.0%
2.75
US$1,042 		379 +0.0% 2.75 US$1,042
2023-05-16 2023-05-15 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
1,715 +0.1%
2.55
US$4,366 		1,715 +0.1% 2.55 US$4,366
2023-05-16 2023-05-12 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,285 +0.2%
2.45
US$5,598 		2,285 +0.2% 2.45 US$5,598
2023-05-08 2023-05-08 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
5,000 +0.4%
2.62
US$13,108 		5,000 +0.4% 2.62 US$13,108
Explore more

More insider trading research around Avalo Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America